113 related articles for article (PubMed ID: 25149112)
1. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?
Asselah T; Bruno S; Craxi A
J Hepatol; 2014 Dec; 61(6):1430-3. PubMed ID: 25149112
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Trifan A; Stanciu C; Gheorghe L; Iacob S; Curescu M; Cijevschi Prelipcean C; Stefanescu G; Girleanu I; Chiriac S; Mihai C; Brisc C; Goldis A; Sporea I; Miftode E; Bataga S; Rogoveanu I; Preda C; Caruntu FA; Singeap AM
Medicine (Baltimore); 2017 Dec; 96(50):e9271. PubMed ID: 29390377
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Sonsuz A; Bozcan S; Hatemi İ; Özdemir S; Canbakan B; Yıldırım S; Gültürk İ; Ar C
Turk J Gastroenterol; 2022 May; 33(5):414-420. PubMed ID: 35678799
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience.
Abd-Elsalam S; Abo-Amer YE; El-Abgeegy M; Elshweikh SA; Elsergany HF; Ahmed R; Elkadeem M; Hawash N; Soliman S; Badawi R; Elguindy AMA; Soliman MY; Mohmed AA; Mansour L
Medicine (Baltimore); 2020 Oct; 99(42):e21972. PubMed ID: 33080669
[TBL] [Abstract][Full Text] [Related]
5. Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.
Huang CF; Jang TY; Lu PL; Yu ML
Medicine (Baltimore); 2016 Nov; 95(47):e5304. PubMed ID: 27893666
[TBL] [Abstract][Full Text] [Related]
6. Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation.
Szymanek-Pasternak A; Rostkowska K; Simon K
BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28918403
[TBL] [Abstract][Full Text] [Related]
7. Therapy of hepatitis C--back to the future.
Liang TJ; Ghany MG
N Engl J Med; 2014 May; 370(21):2043-7. PubMed ID: 24795199
[No Abstract] [Full Text] [Related]
8. Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.
Ravinetto R; De Weggheleire A; Dorlo TP; Francque S; Sokkab A; Pouget C; Meessen B; Tabernero P; Newton PN; Lynen L
Trop Med Int Health; 2016 Dec; 21(12):1490-1495. PubMed ID: 27671365
[No Abstract] [Full Text] [Related]
9. An interferon-free antiviral regimen for HCV after liver transplantation.
Kwo PY; Mantry PS; Coakley E; Te HS; Vargas HE; Brown R; Gordon F; Levitsky J; Terrault NA; Burton JR; Xie W; Setze C; Badri P; Pilot-Matias T; Vilchez RA; Forns X
N Engl J Med; 2014 Dec; 371(25):2375-82. PubMed ID: 25386767
[TBL] [Abstract][Full Text] [Related]
10. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Klibanov OM; Gale SE; Santevecchi B
Ann Pharmacother; 2015 May; 49(5):566-81. PubMed ID: 25680759
[TBL] [Abstract][Full Text] [Related]
11. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.
Lawitz E; Sullivan G; Rodriguez-Torres M; Bennett M; Poordad F; Kapoor M; Badri P; Campbell A; Rodrigues L; Hu Y; Pilot-Matias T; Vilchez RA
J Infect; 2015 Feb; 70(2):197-205. PubMed ID: 25246359
[TBL] [Abstract][Full Text] [Related]
12. Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection.
Asselah T; Marcellin P
Liver Int; 2015 Jan; 35 Suppl 1():56-64. PubMed ID: 25529088
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.
Krishnan P; Beyer J; Mistry N; Koev G; Reisch T; DeGoey D; Kati W; Campbell A; Williams L; Xie W; Setze C; Molla A; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2015 Feb; 59(2):979-87. PubMed ID: 25451055
[TBL] [Abstract][Full Text] [Related]
14. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Sulkowski MS; Eron JJ; Wyles D; Trinh R; Lalezari J; Wang C; Slim J; Bhatti L; Gathe J; Ruane PJ; Elion R; Bredeek F; Brennan R; Blick G; Khatri A; Gibbons K; Hu YB; Fredrick L; Schnell G; Pilot-Matias T; Tripathi R; Da Silva-Tillmann B; McGovern B; Campbell AL; Podsadecki T
JAMA; 2015 Mar 24-31; 313(12):1223-31. PubMed ID: 25706092
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Menon RM; Badri PS; Wang T; Polepally AR; Zha J; Khatri A; Wang H; Hu B; Coakley EP; Podsadecki TJ; Awni WM; Dutta S
J Hepatol; 2015 Jul; 63(1):20-9. PubMed ID: 25646891
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
Eron JJ; Lalezari J; Slim J; Gathe J; Ruane PJ; Wang C; Elion R; Blick G; Khatri A; Hu YB; Gibbons K; Fredrick L; Co M; D'Amico R; Da Silva-Tillmann B; Trinh R; Sulkowski MS
J Int AIDS Soc; 2014; 17(4 Suppl 3):19500. PubMed ID: 25394009
[TBL] [Abstract][Full Text] [Related]
17. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study.
Poordad F; Agarwal K; Younes Z; Cohen D; Xie W; Podsadecki T
Clin Infect Dis; 2015 Feb; 60(4):608-10. PubMed ID: 25365973
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.
Kati W; Koev G; Irvin M; Beyer J; Liu Y; Krishnan P; Reisch T; Mondal R; Wagner R; Molla A; Maring C; Collins C
Antimicrob Agents Chemother; 2015 Mar; 59(3):1505-11. PubMed ID: 25534735
[TBL] [Abstract][Full Text] [Related]
19. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.
Stirnimann G
Expert Opin Pharmacother; 2014 Dec; 15(17):2609-22. PubMed ID: 25347030
[TBL] [Abstract][Full Text] [Related]
20. ABT-450/r-ombitasvir and dasabuvir with ribavirin eliminates viraemia in most patients with HCV infection with cirrhosis.
Martel-Laferrière V
Evid Based Med; 2015 Feb; 20(1):6. PubMed ID: 25209528
[No Abstract] [Full Text] [Related]
[Next] [New Search]
